Letter to the editor: Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs

AIDS Patient Care and STDs

Volumn 22, Issue 5, 2008, Pages 355-357

  Di Biagio, Antonio ^a   Bruzzone, Bianca ^a   Rosso, Raffaella ^a   Viganò, Ottavia ^b   Icardi, Giancarlo ^a   Viscoli, Claudio ^a   Rusconi, Stefano ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ORGANIC COMPOUND; PYRIDAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG EFFICACY; FLOW CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; LETTER; SALVAGE THERAPY; ADULT; CASE REPORT; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; ORGANIC CHEMICALS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 44349089617     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0215     Document Type: Letter

References (8)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 10, 2006. http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf (Last accessed September 8, 2007).
2. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimal background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervetion at 48 weeks in multi-drug reistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475.
3. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in the treatment-experienced patients with-1 infection in POWER1 and 2: Pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
4. Grinsztejn B, Nguyen B-Y, Katlama C, for the protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007;369:1261-1269.
5. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled-trial. Lancet 2007;370:29-38.
6. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125
7. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885-888.
8. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58:714-722.